AR121225A1 - Medios y método para modular los efectos de captación de células inmunitarias - Google Patents
Medios y método para modular los efectos de captación de células inmunitariasInfo
- Publication number
- AR121225A1 AR121225A1 ARP210100243A ARP210100243A AR121225A1 AR 121225 A1 AR121225 A1 AR 121225A1 AR P210100243 A ARP210100243 A AR P210100243A AR P210100243 A ARP210100243 A AR P210100243A AR 121225 A1 AR121225 A1 AR 121225A1
- Authority
- AR
- Argentina
- Prior art keywords
- binds
- modulating
- enhancement
- effects
- binding molecule
- Prior art date
Links
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
Abstract
La presente se relaciona con una composición que comprende un anticuerpo multivalente que consta de un primer dominio variable que se une a un primer antígeno tumoral (TA1), un segundo dominio variable que se une a un segundo antígeno tumoral (TA2) y un tercer dominio variable que se une a un antígeno de captación de células inmunitarias (IEA); y en donde la composición comprende además una segunda molécula de unión que se une a TA1 o TA2. La presente también se relaciona con un kit de partes que comprende el anticuerpo multivalente y la segunda molécula de unión, y con medios y métodos para el tratamiento del cáncer que comprenden la administración al sujeto que lo necesita del anticuerpo multivalente y la segunda molécula de unión.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2024786 | 2020-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR121225A1 true AR121225A1 (es) | 2022-04-27 |
Family
ID=70918920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP210100243A AR121225A1 (es) | 2020-01-29 | 2021-01-29 | Medios y método para modular los efectos de captación de células inmunitarias |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230210988A1 (es) |
EP (1) | EP4097131A1 (es) |
JP (1) | JP7480307B2 (es) |
KR (1) | KR20220133196A (es) |
CN (2) | CN114945596A (es) |
AR (1) | AR121225A1 (es) |
AU (1) | AU2021214622A1 (es) |
CA (1) | CA3166407A1 (es) |
IL (1) | IL294368A (es) |
TW (1) | TW202142568A (es) |
WO (1) | WO2021154073A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020019795A2 (pt) * | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
WO2023166418A2 (en) * | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
WO2023201237A1 (en) * | 2022-04-11 | 2023-10-19 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2965865C (en) | 2002-07-18 | 2021-10-19 | Merus N.V. | Recombinant production of mixtures of antibodies |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
CN112481300A (zh) | 2008-06-27 | 2021-03-12 | 莫鲁斯股份有限公司 | 产生抗体的非人哺乳动物 |
EP3929216A1 (en) | 2008-12-09 | 2021-12-29 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
NO2504364T3 (es) | 2009-11-24 | 2018-01-06 | ||
PT2785375T (pt) | 2011-11-28 | 2020-10-29 | Merck Patent Gmbh | Anticorpos anti-pd-l1 e usos destes |
SI2802607T1 (en) | 2012-01-13 | 2018-01-31 | Julius-Maximilians-Universitaet Wuerzburg | Dual antigen-induced bipartite functional complementation |
MX360110B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
CN104736168B (zh) | 2012-05-31 | 2018-09-21 | 索伦托治疗有限公司 | 与pd-l1结合的抗原结合蛋白 |
MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
US20180194861A1 (en) | 2015-07-10 | 2018-07-12 | Abbvie Inc. | IgM- or IgE-Modified Binding Proteins and Uses Thereof |
AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
SG11201908833TA (en) * | 2017-03-31 | 2019-10-30 | Merus Nv | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
CN110506059B (zh) * | 2017-04-05 | 2023-01-17 | 豪夫迈·罗氏有限公司 | 特异性结合pd1和lag3的双特异性抗体 |
JP7356970B2 (ja) * | 2017-06-25 | 2023-10-05 | システィミューン, インク. | 多重特異性抗体とその作製及び使用方法 |
BR112020019795A2 (pt) | 2018-03-30 | 2021-01-05 | Merus N.V. | Anticorpo multivalente |
JP7427605B2 (ja) | 2018-04-05 | 2024-02-05 | ノバルティス アーゲー | 癌に対する三重特異性結合分子及びその使用 |
-
2021
- 2021-01-28 CA CA3166407A patent/CA3166407A1/en active Pending
- 2021-01-28 IL IL294368A patent/IL294368A/en unknown
- 2021-01-28 AU AU2021214622A patent/AU2021214622A1/en active Pending
- 2021-01-28 CN CN202180009132.9A patent/CN114945596A/zh active Pending
- 2021-01-28 KR KR1020227025506A patent/KR20220133196A/ko active Search and Examination
- 2021-01-28 EP EP21702749.9A patent/EP4097131A1/en active Pending
- 2021-01-28 JP JP2022541676A patent/JP7480307B2/ja active Active
- 2021-01-28 WO PCT/NL2021/050051 patent/WO2021154073A1/en unknown
- 2021-01-28 CN CN202310066791.7A patent/CN116407626A/zh active Pending
- 2021-01-28 US US17/759,728 patent/US20230210988A1/en active Pending
- 2021-01-29 TW TW110103586A patent/TW202142568A/zh unknown
- 2021-01-29 AR ARP210100243A patent/AR121225A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN114945596A (zh) | 2022-08-26 |
EP4097131A1 (en) | 2022-12-07 |
TW202142568A (zh) | 2021-11-16 |
WO2021154073A1 (en) | 2021-08-05 |
IL294368A (en) | 2022-08-01 |
JP7480307B2 (ja) | 2024-05-09 |
JP2023510733A (ja) | 2023-03-15 |
US20230210988A1 (en) | 2023-07-06 |
AU2021214622A1 (en) | 2022-07-21 |
CN116407626A (zh) | 2023-07-11 |
KR20220133196A (ko) | 2022-10-04 |
CA3166407A1 (en) | 2021-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR121225A1 (es) | Medios y método para modular los efectos de captación de células inmunitarias | |
CL2020003179A1 (es) | (divisional de solicitud 713-2015) anticuerpos anti-cd3, moleculas de union a antígeno biespecificas que se unen a cd3 y cd20; y usos de los mismos. | |
AR121302A2 (es) | Conjugados de anticuerpos basados en eribulina y métodos de uso | |
CL2023002805A1 (es) | Anticuerpos multiespecíficos egfr x cd28. | |
CL2019003166A1 (es) | Composición farmacéutica que comprende construcciones de anticuerpos biespecíficas para mejorar el almacenamiento y la administración. | |
AR073775A1 (es) | Anticuerpos biespecificos anti-vegf/anti- ang -2 | |
AR093557A1 (es) | Anticuerpos anti-ceacam5 y usos de estos | |
AR107442A1 (es) | Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer | |
PE20180484A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
AR076195A1 (es) | Anticuerpos biespecificos anti-erbb-1/anti-c-met | |
AR085600A1 (es) | Agentes de union biespecifica | |
PE20170585A1 (es) | Moleculas de union a antigeno biespecificas activadoras de celulas t | |
PE20221326A1 (es) | Anticuerpos anti-mertk y metodos de uso de los mismos | |
BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
BR112016024214B8 (pt) | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal | |
PE20231201A1 (es) | Tratamiento de combinacion | |
BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
MX2021012003A (es) | Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos. | |
MX2022009355A (es) | Anticuerpo anti-mdr1 y uso del mismo. | |
CO2023002959A2 (es) | Neoantígenos ras y usos de los mismos | |
CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
CO2023010208A2 (es) | Proteínas de unión a psma y usos de estas | |
AR121921A1 (es) | Composiciones y métodos de tratamiento del cáncer con receptores de antígeno quimérico | |
MX2022001515A (es) | Composiciones de conjugado de cetuximab-ir700. | |
BR112023002150A2 (pt) | Anticorpos direcionando egfr e uso dos mesmos |